These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29305275)

  • 101. Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases.
    Hu W; Jiang W; Ye L; Tian Y; Shen B; Wang K
    Sci Rep; 2017 Jul; 7(1):5452. PubMed ID: 28710384
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A survey of moyamoya disease in Hawaii.
    Graham JF; Matoba A
    Clin Neurol Neurosurg; 1997 Oct; 99 Suppl 2():S31-5. PubMed ID: 9409401
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Modifiable Risk Factors Associated With Moyamoya Disease: A Case-Control Study.
    Ge P; Zhang Q; Ye X; Liu X; Deng X; Wang J; Wang R; Zhang Y; Zhang D; Zhao J
    Stroke; 2020 Aug; 51(8):2472-2479. PubMed ID: 32640948
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Changes in the clinical spectrum of pediatric moyamoya disease over 40 years.
    Fujioka M; Hara S; Mukawa M; Karakama J; Inaji M; Tanaka Y; Nariai T; Maehara T
    Childs Nerv Syst; 2023 May; 39(5):1215-1223. PubMed ID: 36790492
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Moyamoya in a non-Asian patient: a case report and review of the literature.
    Felbaum D; Henning E; Payne BR
    W V Med J; 2012; 108(2):16, 18-9. PubMed ID: 22655430
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Clinical features, course, and outcomes of a UK cohort of pediatric moyamoya.
    Tho-Calvi SC; Thompson D; Saunders D; Agrawal S; Basu A; Chitre M; Chow G; Gibbon F; Hart A; Tallur KK; Kirkham F; Kneen R; McCullagh H; Mewasingh L; Vassallo G; Vijayakumar K; Wraige E; Yeo TH; Ganesan V;
    Neurology; 2018 Feb; 90(9):e763-e770. PubMed ID: 29483323
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Significance of Serum Angiopoietin-2 in Patients with Hemorrhage in Adult-Onset Moyamoya Disease.
    Yu J; Huang K; Pan J; Shen J; Zhan R
    Biomed Res Int; 2020; 2020():8209313. PubMed ID: 32802878
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Fatal hemorrhagic stroke in a Caucasian girl with moyamoya disease.
    Schödel P; Brawanski A; Friedrich M; Schlachetzki F; Heiss P; Schebesch KM
    Childs Nerv Syst; 2013 Aug; 29(8):1381-5. PubMed ID: 23549955
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients.
    Kraemer M; Schwitalla JC; Diesner F; Aktas O; Hartung HP; Berlit P
    J Neurol; 2019 Jun; 266(6):1421-1428. PubMed ID: 30868219
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Dental Management of a Pediatric Patient with Moyamoya Syndrome: A Rare Clinical Entity.
    Ko BL; Unkel JH
    Pediatr Dent; 2018 Jan; 40(1):56-58. PubMed ID: 29482684
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Association of moyamoya disease with thyroid autoantibodies and thyroid function.
    Lanterna LA; Galliani S; Brembilla C; Longhi L; Gritti P; Bernucci C
    Eur J Neurol; 2017 Feb; 24(2):e9. PubMed ID: 28102046
    [No Abstract]   [Full Text] [Related]  

  • 112. Research progress on moyamoya disease combined with thyroid diseases.
    Zhang G; Liu E; Tan X; Liu C; Yang S
    Front Endocrinol (Lausanne); 2023; 14():1233567. PubMed ID: 37900127
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Characteristics of Moyamoya Disease Based on National Registry Data in Japan.
    Sato Y; Kazumata K; Nakatani E; Houkin K; Kanatani Y
    Stroke; 2019 Aug; 50(8):1973-1980. PubMed ID: 31234758
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Limb-shaking TIA in Moyamoya angiopathy.
    Das S; Ghosh R; Dubey S; Pandit A; Ray BK; Kraemer M
    Clin Neurol Neurosurg; 2021 Aug; 207():106783. PubMed ID: 34225004
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Seizures in Pediatric Moyamoya: Risk Factors and Functional Outcomes.
    Gatti JR; Penn R; Ahmad SA; Sun LR
    Pediatr Neurol; 2023 Aug; 145():36-40. PubMed ID: 37271055
    [TBL] [Abstract][Full Text] [Related]  

  • 116. [Moyamoya disease: revision and description of a number of pedriatic cases].
    Gonzalo-Alonso I; González-Montes NN; Nieto-Barceló JJ; Tomás-Vila M
    Rev Neurol; 2021 Oct; 73(8):261-266. PubMed ID: 34617579
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Long-term mortality in patients with moyamoya angiopathy according to stroke presentation type in South Korea.
    Im SH; Jang DK; Kim H; Park SK; Han KD
    Acta Neurochir (Wien); 2021 Dec; 163(12):3473-3481. PubMed ID: 34427768
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1.
    Brosius SN; Vossough A; Fisher MJ; Lang SS; Beslow LA; George BJ; Ichord R
    Pediatr Neurol; 2022 Sep; 134():85-92. PubMed ID: 35849956
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Clinical and immunopathological features of Moyamoya disease.
    Lin R; Xie Z; Zhang J; Xu H; Su H; Tan X; Tian D; Su M
    PLoS One; 2012; 7(4):e36386. PubMed ID: 22558457
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The relationship between moyamoya disease and bacterial infection.
    Yamada H; Deguchi K; Tanigawara T; Takenaka K; Nishimura Y; Shinoda J; Hattori T; Andoh T; Sakai N
    Clin Neurol Neurosurg; 1997 Oct; 99 Suppl 2():S221-4. PubMed ID: 9409442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.